Bipolar disorder is an important psychiatric disorder with different disease phases. The pharmacological treatment is complicated, and is updated frequently as new research evidence emerges. For the purpose of international collaboration, research, and education, the Taiwan consensus of pharmacological treatment for bipolar disorders was initiated by the Taiwanese Society of Biological Psychiatry and Neuropsychopharmacology (TSBPN) e the Bipolar Chapter, which was established in August 2010 and approved as a member of International Society of Bipolar Disorder. TSBPN is the country member of the World Federation of Societies of Biological Psychiatry (WFSBP). The development of the Taiwan consensus for bipolar disorder was mainly based on the template of WFSBP Guidelines, with references to other international guidelines including the Canadian Network for Mood and Anxiety Treatments, and British Association for Psychopharmacology. We have also added Taiwanese experts' experience, Taiwan national health insurance data, and the indications for the pharmacological treatment of bipolar disorder given by the Taiwan Department of Health, to emphasize the balance between efficacy and safety, and to make this consensus a concise, empirical, and important reference for clinical psychiatric practice.
Introduction
Bipolar disorder is an important mental disorder with mood lability. The international prevalence is 1% for type I, and 1.1% for type II. 1 In Taiwan, the prevalence of bipolar disorder increased from 0.06% in 1996 to 0.4% in 2003, and according to the Taiwan National Health Insurance Research Database, 2e4 there are many patients who were not recognized and treated. Bipolar disorder has different phases, and the pharmacological treatment is complicated, and updated frequently with new research evidence. For the purpose of international collaboration, research, and education, the Taiwan consensus of pharmacological treatment for bipolar disorders was initiated by the Taiwanese Society of Biological Psychiatry and Neuropsychopharmacology (TSBPN) e the Bipolar Chapter, which was established in August 2010 and approved as a member of International Society of Bipolar Disorder (ISBD). TSBPN is the country member of the World Federation of Societies of Biological Psychiatry (WFSBP), therefore, the development of the Taiwan consensus for bipolar disorder was mainly based on the template of WFSBP Guidelines, 5, 6 with references to other international guidelines, including the Canadian Network for Mood and Anxiety Treatments (CNMAT), 1 and British Association for Psychopharmacology (BAP). 7 We also added Taiwanese experts' experience, Taiwan national health insurance data, and the indications for the pharmacological treatment of bipolar disorder given by the Taiwan Department of Health (DOH) to emphasize the balance between efficacy and safety, and to make this consensus a concise, empirical, and important reference for clinical psychiatric practice. The consensus will be updated periodically based on new findings and clinical evidence, under the opinion and recommendation from Taiwan experts. The consensus will not be used as a reference for legal or insurance purposes.
The Taiwan consensus of pharmacological treatment for bipolar disorder includes three treatment phases: manic, depressive, and maintenance. Each pharmacological agent and treatment is listed in Table 1 with four columns: Category of evidence (CE), Taiwan recommendation grade (RG-T), DOH application, and recommended dosage.
CE: six categories from AeF
A. Full evidence from controlled studies. Based on two or more double-blind, parallel-group, randomized controlled trials (RCTs) showing superiority to placebo; and one or more positive RCT showing superiority to or equivalent efficacy compared with established comparator treatment in a three-arm study with placebo control; or in a wellpowered non-inferiority trial. In the case of existing negative studies, these must be outweighed by at least two more positive studies or a meta-analysis of all available studies showing superiority to placebo and non-inferiority to an established comparator treatment. B. Limited positive evidence from controlled studies.
Based on one or more RCTs showing superiority to Although < 10% of patients in acute mania receive monotherapy and some research evidence shows better efficacy of combination of atypical antipsychotics and mood stabilizers than monotherapy, the WFSBP guidelines still suggest that clinicians need to try to maximize the efficacy of monotherapy to avoid the side effects and risk of combination therapy, which is reserved for patients with severe symptoms, or as the subsequent treatment after failure of initial therapy. 11e13 The RG-T of carbamazepine is 2, because of its tolerability and drugedrug interactions. Genotyping HLA-B-1502 has been suggested to reduce the risk of StevenseJohnson syndrome. 14e18 The genotyping is reimbursed by the Taiwan national health insurance. Oxcarbazepine has a similar chemical structure to carbamazepine, with better tolerance and fewer drugedrug interactions, but has a higher risk of hyponatremia. 19, 20 Several small studies have shown inconclusive results for its efficacy for acute mania, 21 so the CE was lowered to C1, and RG-T to level 4. 2. The atypical antipsychotic drugs (second-generation), such as aripiprazole, olanzapine, quetiapine, risperidone, and ziprasidone, have a CE of A and RG-T of 1, and may have better efficacy for dysphoric/mixed/ psychotic manic episodes than lithium has. Olanzapine has more adverse effects such as weight gain and metabolic symptoms.
22,23
A head-to-head comparison showed that haloperidol can control manic symptoms more quickly than quetiapine. 24 Some other studies have suggested higher doses of quetiapine may have better responses, 25 but this was inconclusive. 26, 27 Taking ziprasidone with high-calorie meals can increase its efficacy. 28 3. Other atypical antipsychotic drugs. Paliperidone is the active metabolite of risperidone. The CE of the maximum dose of 12 mg/day is B, but the CE of lower doses (6 and 3 mg/day) is D. 29e31 Taking tolerance into consideration, the RG-T of paliperidone is 2. Although amisulpride is frequently used in clinical practice, only one randomized study, with combination of amisulpride and valproate, showed comparable efficacy of amisulpride and haloperidol, 32 with a CE of B and RG-T of 2. Higher doses of amisulpride may be required for acute mania, but they have a risk of hyperprolactinemia. Clozapine showed efficacy for refractory mania in several open trials with a CE of C1, 33e35 but it was limited to patients with a poor response to other antipsychotics. Clozapine has adverse effects of agranulocytosis, weight gain, and metabolic syndrome, therefore, its RG-T is 3. Several small studies showed the efficacy of zotepine for acute mania with a CE of C1, 36e38 but it had side effects of sedation and extrapyramidal symptoms (EPSs), thus, the RG-T is lowered to 3. 4. Conventional antipsychotic drugs (typical or firstgeneration antipsychotics). Although there is a concern with tolerance, they still have an important role for acute mania with excitement or violence. Conventional antipsychotics, especially at high dose, may exacerbate dysphoric or depressed mood. 39 Haloperidol has a CE of A, but because of EPS side effects and exacerbation of depressed mood, the RG-T is 2. A randomized placebocontrolled study showed efficacy of chlorpromazine for acute mania, 40 and comparable efficacy with lithium. The CE is B, but the RG-T is 3 due to sedative and EPS effects. From the analysis of the Taiwan national health insurance database, other conventional antipsychotics are frequently prescribed, including sulpiride (Dogmatyl), clothiapine (Etumine), fluphenazine (Modecate), flupenthixol (Fluanxol), loxapine (Rosup), thioridazine (Melleril), and trifluoperazine (Stelazine). The CE is C3 and the RG-T is 4 because of the EPS side effects and possible exacerbation of depressed mood. Sulpiride has remained at the level of RG-T 3 due to its lower incidence of EPS adverse effects. 5. Electroconvulsive therapy (ECT) can be used for patients with poor response to other treatments, or under some special conditions, such as pregnancy. The results from chart review and case reports have shown comparable efficacy of ECT and lithium and some types of antipsychotics in acute mania. 41, 42 The response rate is up to 80%. 43 The CE is C1 and RG-T is 4. The repetitive transcranial magnetic stimulation (rTMS) may be a substitute for ECT. However, a single blind study did not show comparable efficacy. 44 6. Combination/augmentation or adjunctive/add-on treatment for the manic phase 1. The research evidence has shown that combination therapy with lithium and divalproex has 1.5-fold better efficacy than monotherapy with either drug. Combined lithium or divalproex with atypical antipsychotics also has better efficacy than monotherapy with lithium or divalproex.
8e10, 45 2. The research evidence has demonstrated no benefit for combined olanzapine and carbamazepine, 46 and a possible increase in the risk of dyslipidemia and weight gain. The combination is not recommended. Table 2) 7.1. Monotherapy for depressive phase 1. Only quetiapine has a CE of A. The research evidence confirms the efficacy of quetiapine monotherapy for depressive episodes, 47e51 with better efficacy than lithium monotherapy, paroxetine, and placebo for improvement of depressive symptoms and remission rate. 52, 53 However, the tolerability and long-term safety need to be considered. The RG-T of quetiapine for the depressive phase is 1. 2. Lamotrigine has a CE of B, 54e56 but is not approved by the US Food and Drug Administration for the depressive phase. However, it is approved by the Taiwan DOH for the indication of bipolar depressive phase. The RG-T is 1 after taking into consideration prevention of depression relapse. Lamotrigine has side effects such as skin rash, StevenseJohnson syndrome, and toxic epidermal necrolysis, therefore, the administration of lamotrigine should be started with low dose and slow titration, and requires close monitoring. 3. The CE of valproate for the depressive phase is B, but the level of RG-T is adjusted to 1 because it is widely 
Depressive phase (
Lithium (or valproate) þ fluoxetine/sertraline/ paroxetine/bupropion 52, 62 There is still no Taiwan empirical data to take into account. Considering that lithium is widely prescribed in clinical practice in Taiwan, and approved by Taiwan DOH, the RG-T is adjusted to 2. 5. The CE of olanzapine is B, which is primarily based on two studies of olanzapine combined with fluoxetine. 63, 64 However, the efficacy of olanzapine monotherapy is still inconclusive, and the side effects of weight gain and metabolic symptoms lower the RG-T to 3. 6. The research evidence for the use of carbamazepine for depressive episodes is inconclusive, 65 with a CE of D and RG-T of 5. There is a concern that more side effects may occur with this combination therapy, especially in the central nervous system and skin. 2. Antidepressants are frequently prescribed for depressive episodes, but there has been a limited number of studies with small sample sizes or short study periods. The best evidence is for combination of olanzapine and fluoxetine, 63 ,64 with a CE of B and RG-T is 3 on account of weight gain and metabolic side effects. Some open trials have shown positive results for quetiapine combined with selective serotonin reuptake inhibitor, leading to a CE of C1 and RG-T of 3. Nonetheless, the evidence for combination of lithium (or valproate) with antidepressants (sertraline/paroxetine/bupropion) is inconsistent and CE is D in the WFSBP guidelines. 66, 67 Due to the Taiwan national insurance database showing that antidepressants are widely prescribed for the depressive episodes in bipolar disorder, the CE has been adjusted to C3 and the RG-T to 3 . Some other open trials have confirmed the efficacy of lithium (or valproate) combined with venlafaxine, Lthyroxine, or topiramate, which has led to a CE of C1. However, the RG-T has been adjusted to < 4 in consideration of the risk of switching to manic episodes. 3. Some studies have shown the efficacy of modafinil or pramipexole adjunctive/add-on therapy to ongoing treatments for bipolar depression, 68e71 leading to a CE of B, but the RG has been adjusted to 4 because of limited clinical use. Adverse skin reactions may be related to high doses of modafinil. 72, 73 4. Analysis of the Taiwan national health insurance database has shown that sulpiride is widely used for depressive episodes. One double-blind study showed that sulpiride has equivalent antidepressant activity to amitriptyline, with faster onset in the first week of the trial, and fewer side effects than amitriptyline. 74 The CE of sulpiride is C1 and the RG-T is 4 due to the side effects of EPSs, such as tardive dyskinesia.
Neurostimulation for the depressive phase
1. For patients with poor response to medication and high risk of suicide, ECT is still an important treatment of choice, 75 with a CE of C1 and RG-T of 4. 2. Research evidence has confirmed the efficacy of rTMS for refractory depression. In Taiwan, a small randomized, double-blind, sham-controlled trial has shown the efficacy of rTMS for refractory unipolar and bipolar depression, 76 but large studies are still limited. The CE of rTMS is C1 and RG-T is 4. The risk of switching to mania is a concern.
Maintenance phase (Table 3)
Maintenance and prophylactic treatment aim to prevent recurrence of new mood episodes. The time period for continuation treatment is defined as the first 6 months after an acute episode, and the maintenance phase of treatment is for months 6e12 after remission of an acute episode. There is no international consensus for the indication for maintenance treatment. The indication for maintenance treatment is more liberally defined in North America and is recommended for all patients after the first episode and ever thereafter. Most European guidelines recommend that maintenance treatment is indicated only after the second episode recurred and with an interval of < 3 years between the two episodes. The WFSBP guidelines, following the Netherland guidelines, 77 suggest that maintenance treatment needs to be administered under the consideration of three factors: frequency of episodes, severity of symptoms, and first-degree relatives with psychiatric disorders. Maintenance treatment is recommended for: (1) patients with first episode, severe symptoms, and psychiatric family history; (2) those with a second episode, with a psychiatric family history or severe symptoms; and (3) those with a third episode.
How long to continue maintenance/prophylactic treatment
There is no international consensus for how long to continue maintenance/prophylactic treatment, 78 because the natural course of bipolar recurrence is around 16e18 months. If the prophylactic treatment only persists for 6e12 months, it is difficult to judge whether to stop the treatment, unless the treatment would have lasted for 2e3 years (Goodwin FK and Jamison KR: ManicDepressive Illness, 2nd Ed: Bipolar Disorders and Recurrent Depression. 2007; p799-801). The duration of maintenance treatment is still based on individual consideration.
Monotherapy for maintenance phase
1. All the three mood stabilizers, lithium, valproic acid, and lamotrigine, have a CE of A and RG-T of 1. However, lithium has more side effects and a twofold risk of discontinuation compared to the other two mood stablizers. Another mood stabilizer, carbamazepine, has a CE of B and the RG-T is elevated to 1 due to fewer side effects of weight gain, and the issue of skin allergy is less of a concern during the maintenance phase. 2. Four atypical antipsychotics, olanzapine, quetiapine, longacting risperidone injection (RLAI), and aripiprazole, all have a CE of A, but RG-T is 2 because of the side effects of weight gain, less efficacy in preventing depressive episodes, and no Taiwan DOH indication for monotherapy (quetiapine or RLAI).
13. Combination/augmentation or adjunctive/add-on therapy for the maintenance phase 1. Combination therapy with lithium/valproic acid and quetiapine may have better efficacy than monotherapy, with a CE of A and RG-T of 1, but may also have more side effects of weight gain and metabolic syndrome. 2. Combination therapy with lithium, divalproex, and carbamazepine is commonly seen in clinical psychiatric practice, with a CE of B and RG-T of 1. 3. Research evidence confirms that combination therapy with lithium/divalproex, lithium, or valproic acid and RLAI, 79 ziprasidone, 80 or aripiprazole, 81, 82 has a CE of A, but with less efficacy for preventing depressive episodes, the RG-T is 2. ; the CE is C1 and RG-T is 3. The side effects of weight gain and metabolic syndrome are of concern. 6. Adjunctive treatment with topiramate, oxcarbazepine, and gabapentin has yielded inconsistent results; the CE is D and RG-T is 4. Topiramate may reduce body weight. 7. Adjunctive ECT is not supported by the results of any randomized or open trial; the CE is F and RG-T is 4. It is only recommended for patients with a poor response to other treatments.
Role of antidepressants in the maintenance phase
The role of antidepressants in maintenance phase treatment is still debatable, although > 50% of patients have residual depressive symptoms. 83 The research evidence about the risk of switching to mania with antidepressants is inconsistent. Only limited evidence supports that antidepressants can prolong the remission period of depression. Most studies have suggested that antidepressants can be only used in combination with mood stabilizers; otherwise, the risk of switch to mania is increased. 84, 85 In addition, the combination of antidepressants with mood stablizers is only suggested for patients with type II bipolar disorder because a higher risk of switching to mania has been reported with type I bipolar disorder. 86 The drug-induced mania switch occurs particularly in those receiving a tricyclic antidepressant or a serotonin and norepinephrine reuptake inhibitor. 84, 87 15. Pharmacotherapy combined with psychosocial intervention improves treatment efficacy Nonpharmacological, psychosocial intervention is important to the success of pharmacotherapy. Psychoeducation can improve patients' insight, facilitate their understanding of the impact of bipolar disorder, and improve self-monitoring, selfregulation, and adherence to medication. 7 Other treatment modalities including group psychotherapy, cognitive behavioral therapy, interpersonal and social rhythm therapy, and family-focused therapy also reduce the relapse rate and improve medication adherence. 5e7, 88 
Treatment of bipolar disorder in women
Pregnancy is a risk period for relapse of bipolar disorders, which occurs in up to 45e52%, or even 70% of cases. For all women of child-bearing age, the plan of pregnancy should be discussed, focusing on the risk of drug use during pregnancy, contraceptive methods, possible interaction of medication and contraceptives, supporting system, genetic inheritance, relapse risk during pregnancy, labor, postpartum, and breast feeding. For patients who are preparing for pregnancy, titrating to discontinuation of medication may take 3e6 months. Medication with the potential for teratogenicity should be avoided. Taking folic acid 5 mg/day is suggested to reduce the risk of teratogenicity. During pregnancy, collaborative care from psychiatrists and gynecologists is important for close monitoring of both the fetus and the mother. Enough sleep and rest are important for preventing relapse of bipolar disorder. to use combination therapy with mood stabilizers (valproic acid or lithium) and atypical antipsychotics (quetiapine, risperidone, or olanzapine). Another 25% of the experts were inclined to use monotherapy with the first choice of DVP, followed by lithium, and then atypical antipsychotics in the sequence of quetiapine, risperidone and finally olanzapine. In the cases with acute hypomania, 87% preferred to use monotherapy (90% mood stabilizers and 10% atypical antipsychotics). The suggested dose was reduced to a half to a third of the dose used in the acute manic phase. Once the hypomanic symptoms disappeared, only 11% of the experts suggested decreasing the dose, and 89% maintained the original dose (50% suggested to maintain for 1e3 months; 27% for 3e6 months; and 12% for 6e12 months). 6. With regard to treatment of bipolar depression, 80% of the experts would like to administer combination treatment and 20% monotherapy. For combination treatment, the distribution was as follows: mood stabilizers þ antidepressants (38%); mood stabilizers þ atypical antipsychotics (25%); atypical antipsychotics þ antidepressants (16%); and antidepressants þ atypical antipsychotics þ mood stabilizers (6.2%). For monotherapy, the first choice was lamotrigine, followed by mood stabilizers (valproic acid, lithium or quetiapine). Experts also suggested that the first choice for combination treatment was (1) lamotrigine þ lithium or quetiapine; or (2) valproic acid þ escitalopram. Professor Sachs from Harvard Medical School reported that there was no different treatment effect between mood stabilizers þ antidepressants and mood stabilizers þ placebo, indicating no beneficial effect of antidepressants for bipolar depression. 66 However, in this questionnaire survey, we found that 70e80% of the experts still used antidepressants in addition to mood stabilizers or atypical antipsychotics to treat bipolar depression. This observation was similar to the recent report at the Annual Meeting of the ISBD in Istanbul, Turkey in March 2012. During combination treatment, the experts preferred to reduce the dose or discontinue antidepressants after symptoms of depression diminished or improved. It was suggested that combination treatment be maintained for 1e3 months (30%), 3e6 months (36%), or > 6 months (only 20%). 7. For the maintenance phase of patients with remitted bipolar disorder, 75% of the experts would maintain combination treatment while the remaining 25% would use monotherapy. With respect to monotherapy, valproic acid was the first choice, followed by lithium and then quetiapine. If mood stabilizers were not chosen, quetiapine would be the first priority, followed by lamotrigine and then risperidone. For combination therapy, the priority use was valproic acid þ quetiapine, lithium or risperidone. The next choice was valproic acid þ olanzapine, or lithium þ quetiapine, selective serotonin reuptake inhibitor or olanzapine. If the bipolar condition became stable and remitted, 35% of the experts maintained treatment for 3e6 months and 38% for 6e12 months. For patients who were refractory to pharmacological treatment, 25% of the experts suggested combined polypharmacy þ cognitive behavioral therapy, followed by 28% with polypharmacy, and 14% with polypharmacy þ ECT. Only 6% needed long-term hospitalization.
